Abstracts tagged "hyperuricemia and uric acid"

Abstract Number: 1296 • 2018 ACR/ARHP Annual Meeting
A Novel Potent and Selective Urate Transporter 1 Inhibitor, NC-2700, with pH-Raising Effect on Low Urinary pH
Masuharu Hirano¹, Takafumi Muto¹, Toshitake Hirai², Promsuk Jutabha³, Naohiko Anzai⁴, Toru Horie⁵, Hitoshi Endou⁶ and Tomio Yamakawa⁷, ¹Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama Prefecture, Japan, ²Nippon Chemiphar Co., Ltd., Misato, Saitama Prefecture, Japan, ³Dokkyo Medical University School of Medicine, Tochigi, Japan, ⁴Chiba University Graduate School of Medicine, Chiba, Japan, ⁵Dethree Res Lab Inc., Tsukuba, Japan, ⁶J-Pharma Co., Ltd., Yokohama, Japan, ⁷Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama prefecture, Japan
Background/Purpose: In most patients with gout, renal underexcretion of uric acid is the main mechanism for hyperuricemia. However, for the risk of uric acid kidney…
Abstract Number: 1120 • 2017 ACR/ARHP Annual Meeting
Less Than Half of Patients Treated with High-Dose Allopurinol Reach Serum Uric Acid Target
Robert Morlock¹, Douglas C.A. Taylor² and Scott Baumgartner³, ¹YourCareChoice, Ann Arbor, MI, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA, ³drB Consulting, Spokane, WA
Background/Purpose: Although allopurinol is FDA approved for up to 800 mg per day and EMEA authorized for up to 900 mg per day, most patients…
Abstract Number: 2057 • 2017 ACR/ARHP Annual Meeting
Identification of Urate Deposits in Patients with Asymptomatic Hyperuricemia Using a Dual-Energy CT Scan
Penny Wang¹, Stacy Smith², Rajesh Garg³, Fengxin Lu¹, Alyssa Wohlfahrt¹, Anarosa Campos¹, Kathleen Vanni⁴, Zhi Yu⁵, Daniel H. Solomon¹ and Seoyoung C. Kim¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Radiology, Division of Musculoskeletal Imaging and Intervention, Brigham and Women's Hospital, Boston, MA, ³Division of Endocrinology, Diabetes & Hypertension, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Serum uric acid (sUA) is a useful indicator of the risk of developing gout. However, most patients with elevated sUA levels do not have…
Abstract Number: 2059 • 2017 ACR/ARHP Annual Meeting
Allopurinol Dose-Titration Patterns Relative to Serum Uric Acid Levels in Gout Patients: US Electronic Health Record Data
An-Chen Fu, Douglas C.A. Taylor and David S. Reasner, Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis and is caused by elevated serum uric acid (sUA). Allopurinol is a first-line urate-lowering therapy…
Abstract Number: 2071 • 2017 ACR/ARHP Annual Meeting
A Novel Selective URAT1 Inhibitor, Tei-a, with Potent Uricosuric Property
Johji Nomura¹, Yoshimasa Takahashi², Kumiko Aoki², Naoki Hase² and Tsunefumi Kobayashi², ¹Teijin Institute for Bio-medical Research, TEIJIN PHARMA LIMITED, Tokyo, Japan, ²TEIJIN PHARMA LIMITED, Tokyo, Japan
Background/Purpose: Hyperuricemia, abnormally elevated level of serum uric acid, is associated with gout as well as other diseases including metabolic syndrome, hypertension, diabetic kidney disease.…
Abstract Number: 2074 • 2017 ACR/ARHP Annual Meeting
A Series of Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Studies to Evaluate the Efficacy, Safety, and Dose-Response Relationship of Orally Administered URC102, a Novel URAT1 Inhibitor, in Korean Patients with Gout
Jae-Bum Jun¹, Howard Lee², Chang-Hee Suh³, Chang Keun Lee⁴, Dong Wook Kim⁵, Jung-Yoon Choe⁶, Sang-Heon Lee⁷, Sang-Hyon Kim⁸, Seung-Jae Hong⁹, So-Young Bang¹⁰, Sung Jae Choi¹¹, Yong-Beom Park¹², Makoto Onohara¹³, Jeongeun Choi¹⁴, Jung Soo Song¹⁵ and Won Park¹⁶, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea, Republic of (South), ³Ajou University School of Medicine, Suwon, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, Inje University College of Medicine, Busan, Korea, Republic of (South), ⁶Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of (South), ⁷Division of Rheumatology, Department of Internal Medicine,, Konkuk University School of Medicine, Seoul, Korea, Republic of (South), ⁸Division of Rheumatology, Department of Internal Medicine, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea, Daegu, Korea, Republic of (South), ⁹Department of Rheumatology, Kyung Hee University Medical Center, Seoul, Korea, Republic of (South), ¹⁰Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ¹¹Internal Medicine, Korea University Medical Center, Seoul, Korea, Republic of (South), ¹²Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of (South), ¹³Science and Strategy, Translational Clinical Research, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan, ¹⁴JW Pharmaceutical Corporation, Seoul, Korea, Republic of (South), ¹⁵Rheumatology, Chung-Ang University College of Medicine, Seoul, Korea, Republic of (South), ¹⁶Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South)
Background/Purpose: URC102 is a novel URAT1 inhibitor under clinical development for the treatment of hyperuricemia with gout. A series of double-blind, placebo-controlled, randomized, multicenter, phase…
Abstract Number: 2078 • 2017 ACR/ARHP Annual Meeting
Hypersensitivity Reactions with Allopurinol and Febuxostat in Adults 65 Years or Older: A Study Using the Medicare Claims Data
Jasvinder A. Singh¹ and John Cleveland², ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology, University of Alabama at Birmingham (UAB), Birmingham, AL
Background/Purpose: Clinicians using allopurinol are always concerned about the risk of rare hypersensitivity reaction. Allopurinol and febuxostat are the two most common urate-lowering agents used…
Abstract Number: 211 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Febuxostat in Advanced CKD Patients with Hyperuricemia
Yoon-Jeong Oh¹, Seung Min Jung¹, Sang-Won Lee², Yong-Beom Park² and Jason Jungsik Song², ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Dosing adjustments and increased risk of serious side effects of uric acid lowering agents in patients with reduced renal function lead to undercorrection of…
Abstract Number: 223 • 2016 ACR/ARHP Annual Meeting
Clinical Predictors of Acute Gout Flares within Hospitalized Patients at a Tertiary Care Center in New York
Lara El Khoury¹, Mohamad Yasmin^1,2, Nabil Zeineddine¹, Joseph Saabiye¹, Saleha Riaz¹, Sami Arnaout¹, Talal El Imad¹, Suzanne El-Sayegh³ and Rita Obeid⁴, ¹Internal Medicine, Staten Island University Hospital, Northwell Health, Staten Island, NY, ²Infectious Diseases, Case Western Reserve University, Cleveland, OH, ³Internal Medicine, Program Director, Staten Island University Hospital, Northwell Health, Staten Island, NY, ⁴Psychology, The Graduate Center, CUNY, New York, NY
Background/Purpose: Gout is the most prevalent inflammatory arthritis worldwide. Within the healthcare setting, gout flares contribute to substantial morbidity and complicated hospital stays. Identifying risk…
Abstract Number: 2158 • 2016 ACR/ARHP Annual Meeting
Serum Uric Acid Is Positively Associated with Pulmonary Function in Korean Health Screening Examinees: A Cross-Sectional Study
Joong Kyong Ahn¹, Jiwon Hwang², Jae-Uk Song³, Hyemin Jeong⁴, Ji Young Chae⁵, Hyungjin Kim⁴, Hoon-Suk Cha⁴ and Eun-Mi Koh⁴, ¹Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Medicine, National Police Hospital, Seoul, Korea, The Republic of, ³Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea, The Republic of, ⁴Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁵Departement of Internal Medicine, Bundang Jesaeng General Hospital, Seongnam, Korea, The Republic of
Background/Purpose: Serum uric acid (SUA) has been shown to be a powerful endogenous antioxidant in the body. The double-edged characteristics of serum uric acid (SUA)…
Abstract Number: 2294 • 2016 ACR/ARHP Annual Meeting
Uric Acid Production and Blood Pressure: The Role of Uric Acid Concentration As Well As Uric Acid Production
Lieke E.J.M. Scheepers^1,2, A. Boonen^1,2, P.C. Dagnelie^2,3,4, M.T. Schram^3,5, C.J.H, van der Kallen^3,5, R.M.A. Henry^3,5, A.A. Kroon^3,5, C.D.A. Stehouwer^3,6 and I.C.W. Arts^3,4,7, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+, Maastricht, The Netherlands, Maastricht, Netherlands, ²CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands, Maastricht, Netherlands, ³CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands, Maastricht, Netherlands, ⁴Department of Epidemiology, Maastricht University, Maastricht, The Netherlands, Maastricht, Netherlands, ⁵Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands, Maastricht, Netherlands, ⁶Internal Medicine, Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands, Maastricht, Netherlands, ⁷MaCSBio Maastricht Centre for Systems Biology, Maastricht University, Maastricht, Netherlands
Background/Purpose: Blood pressure and hypertension are associated with uric acid, the end product of purine catabolism, but the underlying mechanism remainds unclear. During the final…
Abstract Number: 2296 • 2016 ACR/ARHP Annual Meeting
The Influence of Androgen Deprivation Therapy on Serum Uric Acid Level
Jae Hyun Lee¹, Eun Hye Park², Sang Wan Chung³, Jaehyung Hur³, You Jung Ha³, Yeong Wook Song^1,4 and Yun Jong Lee^5,6, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, ⁴Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁵Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
Background/Purpose: The prevalence of hyperuricemia and gout suggests that sex hormones play a role in the gender difference with gout. Estrogen has been thought to…
Abstract Number: 224 • 2015 ACR/ARHP Annual Meeting
Silent Monosodium Urate Crystals Deposits in Asymptomatic Hyperuricemia Lead to a Higher Need for Coronary Revascularization
Mariano Andrés¹, María Amparo Quintanilla², Francisca Sivera³, José Sánchez-Payá⁴, Juan M Ruiz-Nodar⁵, Eliseo Pascual^1,6 and Paloma Vela^1,6, ¹Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ²Sección de Cardiología, Hospital General Universitario de Elda, Alicante, Spain, ³Reumatología, Hospital General Universitario de Elda, Alicante, Spain, ⁴Servicio de Medicina Preventiva, Hospital General Universitario de Alicante, Alicante, Spain, ⁵Servicio de Cardiología, Hospital General Universitario de Alicante, Alicante, Spain, ⁶Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain
Background/Purpose: Increased cardiovascular (CV) risk in gout relates to crystal-driven inflammation. In a preliminary, cross-sectional study we found that silent deposits of monosodium urate (MSU)…
Abstract Number: 2963 • 2014 ACR/ARHP Annual Meeting
The URAT1 Uric Acid Transporter Is Important in Uric Acid Homeostasis and Its Activity May be Altered in Gout Patients and in Drug-Induced Hyperuricemia
Philip K. Tan, Sha Liu and Jeffrey N. Miner, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Gout results from chronic hyperuricemia. Most gout patients exhibit an increased renal reabsorption of uric acid which leads to elevated levels of serum uric…
Abstract Number: 163 • 2013 ACR/ARHP Annual Meeting
The Frequency Of Single Nucleotide Polymorphisms In Urate Transporter Genes and Their Association With Uric Acid Concentration Based On Data From Genome-Wide Association Studies In The Korean Population
Chan-Nam Son¹, So-Young Bang², Sang-Cheol Bae³ and Jae-Bum Jun³, ¹Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, South Korea, ²Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ³Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Gouty arthritis is characterized by hyperuricemia, which results from overproduction of, or impaired renal excretion of, uric acid. Recently, interest has increased in renal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].